Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Additional analysies from 45-month (mo) follow-up of CheckMate 648

被引：0

作者：

Adenis, A. ^{[1
]}

Chau, I. ^{[2
]}

Ajani, J. A. ^{[3
]}

Kitagawa, Y. ^{[4
]}

Xu, J. ^{[5
]}

Wyrwicz, L. S. ^{[6
]}

Motoyama, S. ^{[7
]}

Ogata, T. ^{[8
]}

Kawakami, H. ^{[9
]}

Hsu, C-H. ^{[10
]}

El Hajbi, F. ^{[11
]}

Di Bartolomeo, M. ^{[12
]}

Braghiroli, M. I. ^{[13
]}

Holtved, E. ^{[14
]}

Murphy, M. Blum ^{[15
]}

Zhang, J. ^{[16
]}

Hu, N. ^{[17
]}

Matsumura, Y. ^{[18
]}

Kato, K. ^{[19
]}

Doki, Y. ^{[20
]}

机构：

[1] Inst Canc Montpellier, Dept Med Oncol, Montpellier, France

[2] Royal Marsden Hosp, Dept Med, Surrey, England

[3] Univ Texas MD Anderson Canc Ctr, GI Med Oncol, Houston, TX USA

[4] Keio Univ, Sch Med, Dept Surg, Tokyo, Japan

[5] Acad Mil Med Sci, Affiliated Hosp Canc Ctr, Dept Gastrointestinal Oncol, Beijing, Peoples R China

[6] Narodowy Instytut Onkol, Klin Onkol & Radioterapii, Dept Radiotherapy & Oncol, Warsaw, Poland

[7] Japanese Red Cross Akita Hosp, Dept Surg, Akita, Japan

[8] Kanagawa Canc Ctr, Gastrointestinal Surg, Yokohama, Kanagawa, Japan

[9] Kindai Univ, Fac Med, Med Oncol Dept, Osakasayama, Japan

[10] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[11] Ctr Oscar Lambret, Dept Med Oncol, Lille, France

[12] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy

[13] Univ Sao Paulo, Inst Canc Sao Paulo, Med Oncol Dept, Sao Paulo, Brazil

[14] Odense Univ Hosp, Dept Oncol, Odense, Denmark

[15] Univ Texas MD Anderson Canc Ctr, GI Med Oncol Dept, Houston, TX USA

[16] Bristol Myers Squibb, Oncol Clin Dev, Princeton, NJ USA

[17] Bristol Myers Squibb, China Market Access & Pricing Lead, Princeton, NJ USA

[18] Ono Pharmaceut Co Ltd, Oncol Clin Dev, Osaka, Japan

[19] Natl Canc Ctr, Dept Gastrointestinal Med Oncol, Tokyo, Japan

[20] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Osaka, Japan

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.05.313

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

398P

引用

页码：S161 / S162

页数：2

共 50 条

[1] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648
Chau, Ian
Ajani, Jaffer A.
Kitagawa, Yuko
Xu, Jianming
Wyrwicz, Lucjan S.
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Braghiroli, Maria Ignez
Holtved, Eva
Murphy, Mariela A. Blum
Nathani, Raheel
Hu, Nan
Matsumura, Yasuhiro
Kato, Ken
Doki, Yuichiro
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648
Greil, R.
Kato, K.
Ajani, J.
Doki, Y.
Xu, J.
Wyrwicz, L.
Motoyama, S.
Ogata, T.
Kawakami, H.
Hsu, C. -H
Adenis, A.
El Hajbi, F.
Di Bartolomeo, M.
Braghiroli, M. Ignez
Holtved, E.
Murphy, M. Blum
Patel, A.
Hu, N.
Matsumura, Y.
Chau, I
Kitagawa, Y.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 242 - 243
[3] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.
Kato, Ken
Ajani, Jaffer A.
Doki, Yuichiro
Xu, Jianming
Wyrwicz, Lucjan
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Braghiroli, Maria Ignez Freitas Melro
Holtved, Eva
Murphy, Mariela A. Blum
Patel, Apurva
Hu, Nan
Matsumura, Yasuhiro
Chau, Ian
Kitagawa, Yuko
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 290 - 290
[4] Nivolumab (NIVO) plus chemotherapy (chemo) or NIVO plus ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first report of the CheckMate 648 study
Greil, R.
Chau, I
Doki, Y.
Ajani, J. A.
Xu, J.
Wyrwicz, L.
Motoyama, S.
Ogata, T.
Kawakami, H.
Hsu, C. -H
Adenis, A.
el Hajbi, F.
Di Bartolomeo, M.
Braghiroli, Ignez M.
Holtved, E.
Xynos, I
Liu, X.
Lei, M.
Kondo, K.
Kato, K.
Kitagawa, Y.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 81 - 82
[5] Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
Chau, Ian
Doki, Yuichiro
Ajani, Jaffer A.
Xu, Jianming
Wyrwicz, Lucjan
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Freitas Melro Braghiroli, Maria Ignez
Holtved, Eva
Xynos, Ioannis
Liu, Xuan
Lei, Ming
Kondo, Kaoru
Kato, Ken
Kitagawa, Yuko
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18)
[6] Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648.
Lei, Ming
Doki, Yuichiro
Kitagawa, Yuko
Kato, Ken
Chau, Ian
Yao, Jin
Xu, Jianming
Wyrwicz, Lucjan S.
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Braghiroli, Maria Ignez
Holtved, Eva
Blum Murphy, Mariela A.
Novosiadly, Ruslan
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 252 - 252
[7] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648
Chau, I.
Ajani, J.
Doki, Y.
Xu, J.
Wyrwicz, L.
Motoyama, S.
Ogata, T.
Kawakami, H.
Hsu, C.
Adenis, A.
El Hajbi, F.
Di Bartolomeo, M.
Braghiroli, M.
Holtved, E.
Murphy, M. Blum
Abdullaev, S.
Soleymani, S.
Lei, M.
Kato, K.
Kitagawa, Y.
ANNALS OF ONCOLOGY, 2022, 33 : S379 - S380
[8] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.
Chau, Ian
Ajani, Jaffer A.
Doki, Yuichiro
Xu, Jianming
Wyrwicz, Lucjan
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Braghiroli, Maria Ignez Freitas Melro
Holtved, Eva
Murphy, Mariela A. Blum
Abdullaev, Sandzhar
Soleymani, Samira
Lei, Ming
Kato, Ken
Kitagawa, Yuko
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
Janjigian, Y. Y.
Ajani, J. A.
Moehler, M.
Garrido, M.
Gallardo, C.
Shen, L.
Yamaguchi, K.
Wyrwicz, L.
Skoczylas, T.
Bragagnoli, A.
Liu, T.
Tehfe, M.
Elimova, E.
Li, M.
Poulart, V.
Lei, M.
Kondo, K.
Shitara, K.
ANNALS OF ONCOLOGY, 2021, 32 : S1329 - S1330
[10] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate
Moehler, Markus
Janjigian, Yelena Y.
Shitara, Kohei
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Bruges, Ricardo
Cleary, James M.
Karamouzis, Michalis
Soleymani, Samira
Lei, Ming
Chanaga, Carlos Amaya
Ajani, Jaffer A.
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 64 - 64

← 1 2 3 4 5 →